Mechanism of action of 5‐arninosalicylic acid

Abstract

Mediators of Inflammation,1,[151][152][153][154][155][156][157][158][159][160][161][162][163][164][165] (1992) 5-AMINOSALICYLIC ACID (5-ASA) has been used for over 50 years in the treatment of inflammatory bowel disease in the pro-drug form sulphasalazine (SASP). SASP is also used to treat rheumatoid arthritis. However whether the therapeutic properties of SASP are due to the intact molecule, the 5-ASA or sulphapyridine components is unknown. Several mechanisms of action have been proposed for 5-ASA and SASP including interference in the metabolism of arachidonic acid to prostaglandins and leukotrienes, scavenging,of reactive oxygen species, effects on leucocyte function and production of cytokines. However, it is unlikely that the anti-inflammatory properties of SASP and 5-ASA are due to several different properties but more likely that a single property of 5-ASA explains the theraapeutic effects of 5-ASA and SASP. Reactive oxygen species (ROS) are involved in the metabolism of prostaglandins and leukotrienes and can act as second messengers, and so the scavenging of ROS may be the single mechanism of action of 5-ASA that gives rise to its antiinflammatory effects in both inflammatory bowel disease and rheumatoid arthritis.

The Impact of Preoperative Immunomodulation on Pouch-Related Septic Complications After Ileal Pouch-Anal Anastomosis

“…However, the exact mechanism of action of 5-ASA in the treatment of ulcerative colitis remains unknown, and there is good evidence that it works by facilitating healing rather than by preventing inflammation. 21 This may explain the lower incidence of late sepsis in our patients who were taking 5-ASA preoperatively.…”

Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal

“…5‐Aminosalicylic acid (5‐ASA) was not considered an immunosuppressive drug, thus data regarding this were not collected. Previous data support the evidence that 5‐ASA facilitates healing rather than impairing it [11]. The control group included patients who had not received infliximab, steroids or any other immunosuppressive modulation for at least 8 weeks before stoma closure or within 1 month following the initial surgery.…”

Investigation of the Electrochemical Behavior of Mesalazine on the Surface of a Glassy Carbon Electrode Modified with CNT/PPY Doped by 1,5‐Naphthalenedisulfonic Acid

“…The role of MSA in combination therapy to improve efficacy and concomitant drug pharmacokinetics or in chemoprevention against inflammatory bowel disease (IBD)‐related colonic carcinoma has not yet been completely elucidated 4. According to the literature MSA acts by blocking the production of prostaglandins and leukotrienes, inhibiting bacterial peptide‐induced neutrophil chemotaxis and adenosine‐induced secretion, scavenging reactive oxygen metabolites 5–7.…”